Literature DB >> 23771406

A composite scale applied to evaluate anxiety in schizophrenic patients (SAES).

Pierre-Michel Llorca1, Christophe Lancon, Olivier Blanc, Ingrid de Chazeron, Ludovic Samalin, Hervé Caci, Jean-Alexandre Lesturgeon, Franck J Bayle.   

Abstract

Anxiety in schizophrenia possesses specific features and is difficult to assess because no specific evaluating tool is currently available. The aim of this study was to develop and validate a hetero-assessment-based scale to specifically measure anxiety in schizophrenia. A literature review and a survey among psychiatrists allowed the selection of 29 items from 4 previous scales evaluating anxiety. Factor analysis allowed building up a final 22-item composite scale of anxiety evaluation in schizophrenia (SAES), which was then validated in 147 schizophrenic patients. One hundred and forty-seven (147) schizophrenic patients (70.8 % male, mean age = 36.9 years) were included in the study. Principal component analysis of the SAES revealed three factors, namely "expressed and perceived anxiety," "somatic anxiety," and "anxiety and environment". All total and factor scores of the SAES were significantly correlated (p < .001) with total and factor scores of the original scales. Finally, the SAES showed good inter-rater reliability [intra-class correlation coefficient (ICC) = .82]. In conclusion, a specific tool for evaluating anxiety in schizophrenia (SAES) was developed and validated in a sample of schizophrenic patients. The SAES can be useful to investigate clinical, psychopathological, and therapeutic aspects of anxiety in schizophrenia.

Entities:  

Mesh:

Year:  2013        PMID: 23771406     DOI: 10.1007/s00406-013-0416-1

Source DB:  PubMed          Journal:  Eur Arch Psychiatry Clin Neurosci        ISSN: 0940-1334            Impact factor:   5.270


  37 in total

Review 1.  The Delphi technique.

Authors:  N Bowles
Journal:  Nurs Stand       Date:  1999 Jul 28-Aug 3

2.  [Efficacy of zuclopenthixol acetate on psychotic anxiety evaluated in an open study].

Authors:  J L Romain; P Dermain; P Greslé; S Grignon; P Moisan; D Nore; G Pech; J Benyaya; I Perret
Journal:  Encephale       Date:  1996 Jul-Aug       Impact factor: 1.291

3.  The quality of life of the mentally ill living in residential facilities: findings from a national survey in Italy.

Authors:  Angelo Picardi; Paola Rucci; Giovanni de Girolamo; Giovanni Santone; Gabriele Borsetti; Pierluigi Morosini
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2006-06-20       Impact factor: 5.270

4.  Deficits in theory of mind and social anxiety as independent paths to paranoid features in schizophrenia.

Authors:  Paul H Lysaker; Giampaolo Salvatore; Megan L A Grant; Michele Procacci; Kyle L Olesek; Kelly D Buck; Giuseppe Nicolò; Giancarlo Dimaggio
Journal:  Schizophr Res       Date:  2010-07-22       Impact factor: 4.939

5.  Depressive signs and symptoms in schizophrenia: a prospective blinded trial of olanzapine and haloperidol.

Authors:  G D Tollefson; T M Sanger; Y Lu; M E Thieme
Journal:  Arch Gen Psychiatry       Date:  1998-03

6.  Longitudinal analysis of subjective quality of life in schizophrenia: anxiety as the best symptom predictor.

Authors:  J D Huppert; T E Smith
Journal:  J Nerv Ment Dis       Date:  2001-10       Impact factor: 2.254

Review 7.  How prevalent are anxiety disorders in schizophrenia? A meta-analysis and critical review on a significant association.

Authors:  Amélie M Achim; Michel Maziade; Eric Raymond; David Olivier; Chantal Mérette; Marc-André Roy
Journal:  Schizophr Bull       Date:  2009-12-03       Impact factor: 9.306

8.  Antipsychotic and anxiolytic properties of risperidone, haloperidol, and methotrimeprazine in schizophrenic patients.

Authors:  O Blin; J M Azorin; P Bouhours
Journal:  J Clin Psychopharmacol       Date:  1996-02       Impact factor: 3.153

9.  Effects of cognitive remediation therapies on psychotic symptoms and cognitive complaints in patients with schizophrenia and related disorders: a randomized study.

Authors:  Laurent Lecardeur; Emmanuel Stip; Michel Giguere; Guy Blouin; Jean-Pierre Rodriguez; Maud Champagne-Lavau
Journal:  Schizophr Res       Date:  2009-04-22       Impact factor: 4.939

10.  Social anxiety in outpatients with schizophrenia: a relevant cause of disability.

Authors:  Stefano Pallanti; Leonardo Quercioli; Eric Hollander
Journal:  Am J Psychiatry       Date:  2004-01       Impact factor: 18.112

View more
  2 in total

Review 1.  Anxiety in Patients with Schizophrenia: Epidemiology and Management.

Authors:  Henk Temmingh; Dan J Stein
Journal:  CNS Drugs       Date:  2015       Impact factor: 5.749

2.  The new risk variant CACNA1C and brain circuits in schizophrenia.

Authors:  Andrea Schmitt; Peter Falkai
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2014-03       Impact factor: 5.270

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.